signal/raiseTrack rounds
Series BHealthtech & bio · Hong Kong

Yicura BioMed closes first tranche of Series B led by Gobi Partners for its HIV vaccine

The Hong Kong biotech, formerly Immuno Cure, will use the money to take its therapeutic HIV vaccine ICVAX into a Phase II trial. It did not disclose the amount.

s/rFunding deskEast Asia · 2 min read

Yicura BioMed, a clinical-stage biotech at Hong Kong Science Park, completed the first closing of its Series B round, it announced on 12 November 2026. Gobi Partners, the Asia-focused venture firm, led the round.

Strategic investors from Wuxi and institutional investors from Hong Kong also took part, but none of them were named. The company did not disclose the amount raised, a valuation or a target size for the full round, and it gave no date for a final close.

Yicura was formerly known as Immuno Cure. Gobi Partners has backed the company before: according to TNGlobal, a fund managed by Gobi Partners GBA led a $12m first tranche of a planned $27m Series A in 2023.

“This funding round marks an important step in Yicura's growth as we move ICVAX® from early clinical validation towards efficacy studies.”Dr. Xia Jin, Co-Founder and CEO, Yicura BioMed

What Yicura is developing

Yicura develops immunotherapies for infectious diseases, cancers and inflammatory diseases. Its work is based on two patented platforms: a DNA vaccine enhanced with PD-1 and an antibody that targets a variant of PD-1 known as Delta42PD1.

Its lead product is ICVAX, a therapeutic DNA vaccine for HIV. It completed a randomised, placebo-controlled Phase I trial, approved by China's drug regulator, in people living with HIV who were already on antiretroviral therapy. The company said the vaccine performed well on safety and on the immune response it produced.

The next step is a Phase II trial to test whether ICVAX works. Yicura said the aim is longer-lasting immune control of HIV, with a functional cure as the long-term goal. TNGlobal noted that no start date for Phase II enrolment had been announced and that good Phase I safety and immune-response results do not show that a treatment works.

Who invested

Gobi Partners was founded in 2002 and has offices in Hong Kong and Kuala Lumpur. It says it manages $2bn across more than 30 investment vehicles. Fred Li, its managing director and head of university ventures, said Yicura's platforms could extend beyond a single disease to precision cancer therapies, and that Gobi was pleased to lead the round.

Chief executive Xia Jin, a co-founder, thanked Gobi and the other investors and said the company was encouraged by the Phase I data for ICVAX. Jin said the company sees potential in both of its platforms to address unmet needs in infectious diseases, cancers and inflammation.

Gobi says it works with universities to bring research into commercial companies, and that it has more than 400 portfolio companies and 76 exits. Neither side disclosed Gobi's ownership stake in Yicura.

What the money is for

Yicura will use the money to move ICVAX towards Phase II and to speed up its cancer programmes across both the vaccine and antibody platforms. It did not give timelines for the cancer programmes, and it did not disclose headcount or its total funding to date.

Because this was only a first close, more investors may join the Series B before it is complete. The strategic investors from Wuxi give the company backers in mainland China, where its Phase I trial was approved by the national drug regulator.

Company website: yicura.hk